Tumor Microenvironment‐Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade
Shenyang Pharmaceutical University · Chinese Academy of Sciences · +4 more institutions
Abstract
Chemoimmunotherapy is reported to activate a robust T cell antitumor immune response by triggering immunogenic cell death (ICD), which has initiated a number of clinical trials. However, current chemoimmunotherapy is restricted to a small fraction of patients due to low drug delivery efficacy and immunosuppression within the tumor microenvironment. A tumor microenvironment-activatable prodrug vesicle for cancer chemoimmunotherapy using ICD is herein reported. The prodrug vesicles are engineered by integrating an oxaliplatin (OXA) prodrug and PEGylated photosensitizer (PS) into a single nanoplatform, which show tumor-specific accumulation, activation, and deep penetration in response to the tumoral acidic and…
Citation impact
- FWCI
- 28.70
- Percentile
- 100%
- References
- 43
Authors
8- FZFangyuan Zhou
Shenyang Pharmaceutical University, Chinese Academy of Sciences, Shanghai Institute of Materia Medica
- BFBing Feng
Chinese Academy of Sciences, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences
- HYHaijun YuCorresponding
Chinese Academy of Sciences, Shanghai Institute of Materia Medica
- DWDangge Wang
Chinese Academy of Sciences, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences
- TWTingting Wang
Chinese Academy of Sciences, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences
Topics & keywords
- Chemoimmunotherapy
- Immunogenic cell death
- Tumor microenvironment
- Cancer research
- Prodrug
- Immune system
- CD47
- Medicine
- Good health and well-being